ENJAYMO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Finland, France, Ireland, Israel, Italy, Japan, Lithuania.

Active ingredients

The drug ENJAYMO contains one active pharmaceutical ingredient (API):

1	Sutimlimab UNII GNWE7KJ995 - SUTIMLIMAB
	Sutimlimab is an IgG, subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease that cleaves C4. The activities of the lectin and alternative complement pathways are not inhibited by sutimlimab. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of red blood cells, resulting in inhibition of haemolysis in patients with CAD.
	Read more about Sutimlimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ENJAYMO Solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AJ04		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	033391
FR	Base de données publique des médicaments	69505243
IL	מִשְׂרַד הַבְּרִיאוּת	9207
IT	Agenzia del Farmaco	050307014, 050307026
JP	医薬品医療機器総合機構	6399431A1023
LT	Valstybinė vaistų kontrolės tarnyba	1095972, 1095973
US	FDA, National Drug Code	80203-347